ascopubs.org

Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer.

Age-specific trends of survival in metastatic breast cancer: Data from a population-based cancer registry in Stockholm, Sweden. Background: Lapatinib (L) is a selective dual EGFR and HER2 inhibitor.
Nature

HER2 and EGFR status and correlation with response to lapatinib and chemotherapy

Lapatinib inhibits HER2 and EGFR, but which patients with breast cancer are most likely to benefit from this treatment is unclear. Press et al. assessed the DNA, mRNA and protein level status of HER2 ...
ascopubs.org

Phase II trial of lapatinib in patients in stage D0 prostate cancer (E5803): Effect of Kras and EGFR status on clinical outcome.

Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant ...
Medscape

Mechanisms of Disease: Understanding Resistance of HER2-Targeted Therapy in Human Breast Cancer

The EGFR family consists of four different members: EGFR; human epidermal growth factor receptor (HER) 2; HER3; and HER4. Upon ligand binding, these receptors can homodimerize or heterodimerize with ...
Medscape

Genetic Characterization to Improve Interpretation and Clinical Management of Hepatotoxicity Caused by Tyrosine Kinase Inhibitors

†Data from lapatanib-treated patients with metastatic breast cancer [43,93]. ‡Data from pazopanib-treated patients with renal cell carcinoma [31]. §This is a definition of a possible Hy's law case, ...
The American Journal of Managed Care

New Molecular Drivers of HER2 Breast Cancer Resistance: A Q&A With Ateequllah Hayat, PhD

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer. Approximately 70% of patients with breast cancer ...